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Neural cancers display cellular hierarchies with self-renewing tumorigenic cancer stem cells (CSCs) at the
apex. Instructive cues to maintain CSCs are generated by both intrinsic networks and the niche microenvi-
ronment. The CSC-microenvironment relationship is complex, as CSCs can modify their environment and
extrinsic forces induce plasticity in the cellular hierarchy.Neural cancers represent a diverse set of over 100 diagnoses
that collectively cause significant morbidity and mortality. The
most common primary brain tumor, glioblastoma multiforme
(GBM), is nearly universally lethal with a five-year survival rate
of 2%, and current therapies only offer palliative relief. As the
name implies, GBMs display striking cellular heterogeneity,
which may be responsible for the frequent progression or recur-
rence in nodular or regional patterns observed in patients.
Models to explain the origin of tumor cellular heterogeneity
include a stochastic model in which tumor cells have a random
probability of developing mutations to permit tumor mainte-
nance and a hierarchical model in which sustained tumor growth
is restricted to selected subpopulations, called cancer stem cells
(CSCs). Recently, the Dick and Greaves laboratories presented
leukemia studies suggesting that these two models are not
mutually exclusive, but rather that tumor cell evolution may
involve simultaneous changes governed by both models (com-
mented on in Burgess, 2011). Based on the concept that cancers
are organ systems governed by aberrant development and
homeostasis, the CSC hypothesis is consistent with the exis-
tence of cellular populations that maintain tumor growth through
self-renewal and generation of the larger tumor bulk in coopera-
tion with a supportive microenvironment. Numerous laboratories
have demonstrated the existence of CSCs in several high-grade
primary brain tumors (gliomas, medulloblastomas, and ependy-
momas) and neuroblastomas, but CSCs from lower-grade
tumors are less clearly defined. CSCs in neural cancers display
similarities with neural stem cells (NSCs) in terms of their
capacity for self-renewal and sphere-forming growth in serum-
free conditions, their stem cell marker expression, and their
multilineage differentiation potential. However, CSCs and
NSCs can also be distinguished based on aberrant expression
of differentiation markers, chromosomal abnormalities, and
tumor formation. It is important to note that the CSC hypothesis
does not require a stem cell cell-of-origin and that different
cancers appear to originate from stem cells, lineage-restricted
precursors, or more than one cell type.
Sizing Up the Roster
Several sources of confusion have challenged the concepts
inherent to the CSC model, including discrepancies in the
nomenclature utilized by members of the field. Some reports482 Cell Stem Cell 8, May 6, 2011 ª2011 Elsevier Inc.have employed the term ‘‘tumor-initiating cells,’’ but this desig-
nationmay inadvertently confuse the idea of which cell is respon-
sible for originating the disease, as opposed to reflecting the
capacity of isolated cancer cells to replicate a tumor in vivo. In
contrast, CSCs are better described as tumor-propagating cells
that also generate the nontumorigenic tumor cells that do not
contribute to secondary transplantation assays. For the scope
of this review, the fraction of tumor-forming cells in a transplanta-
tion assay will be referred to as CSCs, but it should be acknowl-
edged that the premise that the bulk tumor arises exclusively
downstream of CSCs has not been fully validated in most
cancers. Finally, it is also important to consider that CSCs
need not be rare, and the ability to prospectively identify and
enrich for CSCs using a single set of markers (i.e., an immuno-
phenotype) is not universal for any cancer, perhaps reflecting
the intertumoral diversity within cancer subtypes. Several
genetic and expression studies, including those of Philips,
Parsons, and the Cancer Genome Atlas, have distinguished at
least two GBM tumor subtypes (proneural and mesenchymal)
that are enriched for different genetic lesions, but the relationship
between these tumor subgroups and CSCs remains to be
defined (reviewed in Huse et al., 2011). Despite these difficulties,
neural CSCs have been heavily studied due to their implied role
in promoting resistance to conventional therapies and their
potential contribution to tumor recurrence.
BecauseCSCsmay contribute to treatment failure, elucidating
the molecular pathways that regulate CSC maintenance and
survival may inform the development of novel therapies. Intrinsic
regulation of CSCs occurs through key proliferative and survival
pathways including c-Myc, Oct4 (POU5F1), Olig2, and Bmi1 (re-
viewed in Li et al., 2009b). Extrinsically, CSCs are regulated by
growth factors as well as cell-cell and cell-extracellular matrix
(ECM) interactions. Extrinsic interactions occur in distinct
anatomical locations, termed microenvironments or niches.
These niches are responsible for CSC maintenance and may
have a role in promoting therapeutic resistance (Rosen and
Jordan, 2009). In the context of neural CSCs, the concept of
a niche is likely to be mitogenic rather than quiescent, as it
remains unclear whether a quiescent neural CSC exists. Under-
standing CSCs and their niches in one cancer may have broad
implications for other tumors, as the CSC niche for one tumor





Figure 1. Microenvironmental Factors
Modulate Intrinsic Cancer Stem Cell
Pathways
Cancer stem cells (CSC) in neural tumors (A) are
enriched in niches including hypoxic regions (B),
the perivascular compartment (C), and possibly
the invasive edge (D).
(B) Regions of hypoxia in neural tumors have been
well characterized near areas of necrosis. Recent
studies have suggested that low oxygen helps to
maintain the CSC population, therefore support-
ing hypoxic regions as a niche for CSCs. Hypoxia
modulates cell phenotypes via HIF signaling,
which drives expression of stem cell-related
genes.
(C) The perivascular niche is themost well-defined
CSC niche in neural tumors. Experimental
evidence has demonstrated that cells expressing
integrin a6 are localized in the perivascular region,
denoted by CD31-positive endothelial cells of
the blood vessel. Interaction of the integrin cell-
surface proteins with the extracellular matrix
(ECM) within the perivascular space supports
CSC maintenance in gliomas. Notch-ligand inter-
action between endothelial cells of the blood vessels and the cancer cell is also crucial for CSC maintenance, but the crosstalk between key signaling receptors
such as integrins and Notch is yet to be fully elucidated. Inhibition of the Notch pathway has been shown to have detrimental effects on the CSC phenotype aswell
as survival following irradiation in gliomas.
(D) The invasive front of neural tumors is thought to contain CSCs and provide an interface of interactions with immune cells and normal brain stroma. It is
hypothesized that the microenvironment of these invasive regions supports CSC maintenance. However, the invasive niche has not been well characterized.
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CSC niches. Moving beyond the idea that niches regulate CSC
maintenance, recent work has demonstrated that the bidirec-
tional communication between CSCs and their microenviron-
ment has the ability to influence cell fate in GBMs (Bautch,
2010; Heddleston et al., 2009; Hjelmeland et al., 2011). Better
defining how CSCs interact with their microenvironment has
direct implications on the basic biology of the tumor and is likely
to provide insight into the design of more effective therapies.
Several models have been employed to interrogate the nature
of communication between CSCs and the niche. Currently,
however, no system exists to fully recapitulate the genetic and
epigenetic diversity representative of the human condition.
Immunodeficient animal models are often used for in vivo
assays, but this approach fails to replicate the immune system
component that is present in human patients and that may serve
as a powerful driver of cellular hierarchy. Highly immunocompro-
mised systems, such as the NSG-SCID model, have been
proposed as an improvement over other systems, largely due
to the higher frequency of tumor growth in thesemore permissive
systems. However, it has yet to be proven that such models
better represent tumor growth patterns that occur in humans,
and it is possible that their immunocompromised status may
permit growth of tumor cells that would not occur in patients.
In contrast, genetically engineered models may yield syngeneic
hosts that eliminate the presence of artificial immunemodulation
and species differences in cytokine signaling but still pose chal-
lenges with respect to their relative lack of cellular heterogeneity.
Tumorigenesis can be classified into spontaneous models (e.g.,
the Ptch medulloblastoma model), and models that require
manipulation may induce inflammation prior to tumor initiation
(e.g., medulloblastomas and GBMs from the Nestin tv-a model).
Furthermore, manipulated tumor models may contain cells that
express stem cell markers but do not fully recapitulate tumorformation and thus lack a predicted CSC hierarchy. Whether
these differences reflect different tumor subtypes or suggest
loss of hierarchy with different models has yet to be defined.
Thus, no single model can provide for complete characterization
of CSC microenvironmental interplay, and thus, achieving an
appropriately bidirectional model will likely require the combina-
tion of complementary approaches.
Support from the Sidelines
NSCs commonly reside in perivascular regions, which exhibit
restricted oxygen availability and distinct ECM profiles. In
parallel, neural CSCs are enriched in perivascular niches, and
possibly also within regions of hypoxia and at the invasive
edge of the tumor (Figure 1). The perivascular niche is the best
characterized CSC niche due to the established relationship
between tumor growth and angiogenesis. In a variety of brain
cancers, CSCs are located within close proximity to blood
vessels, which facilitates the transfer of signals necessary for
their maintenance (as demonstrated in a 2007Cancer Cell report
from Gilbertson and colleagues, who examined GBM, ependy-
moma, and medulloblastoma samples; reviewed in Gilbertson
and Rich, 2007). In the same vein, Bao et al. provided evidence
that GBM CSCs secrete vascular endothelial growth factor
(VEGF) that stimulates endothelial cell growth to support a local
vascular environment (reviewed in Gilbertson and Rich, 2007). In
turn, endothelial cells express Notch ligands that may stimulate
Notch receptors essential for CSC maintenance (Fan et al.,
2010). Endothelial cells may also secrete nitric oxide to activate
the Notch pathway (Charles et al., 2010). CSCs are also regu-
lated through ECM receptors, such as integrin a6, that are en-
riched on GBM CSCs and promote their maintenance (Lathia
et al., 2010). Continuing studies elucidating the potential
signaling crosstalk at the cell surface between key proteins
such as integrins, Notch, and growth factor receptors may clarifyCell Stem Cell 8, May 6, 2011 ª2011 Elsevier Inc. 483
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CSC niche is supported by studies from Bao and coauthors
demonstrating that GBM CSCs display resistance to conven-
tional therapies (reviewed in Gilbertson and Rich, 2007). This
work was extended in a mouse model of medulloblastoma
whereby tumor cells within the perivascular space were resistant
to radiation via Akt signaling, which, when targeted, resulted in
greater radiation efficiency (Hambardzumyan et al., 2008).
Thus, the perivascular niche may offer an indirect CSC thera-
peutic target, e.g., for anti-VEGF interventions such as bevacizu-
mab (reviewed in Gilbertson and Rich, 2007). The limited clinical
success of bevacizumab, complicated by posttreatment inva-
sion, warrants further understanding of perivascular regulation
in GBM development and therapies.
The metabolic demands of rapidly proliferating tumors often
exceed local supply, necessitating neovasculature, but newly
formed vessels are often inefficient. Given the plasticity of
cancer, which extends to the CSC compartment, recent work
by Ricci-Vitiani et al. and Wang et al. suggests that GBM CSCs
can directly participate in vasculogenic processes (reviewed
by Bautch, 2010). These groups both identified endothelial cells
in GBM microvessels that contained tumor-specific chromo-
somal aberrations, suggesting that these endothelial cells were
of tumor origin. Furthermore, CSCs isolated from GBMs could
differentiate into endothelial-like cells both in vitro and in vivo,
suggesting that the tumor cells were able to cross lineage
boundaries via some degree of transdifferentiation. These find-
ings may have profound implications on our understanding and
therapeutic approaches to cancer. CSCs may be opportunistic,
in that when key microenvironment components are not readily
available, they can exhibit lineage plasticity and give rise to
progeny that supply the deficient cell type. Theoretically, this
process may also occur in other tumor components such as
the stroma and tumor-related immune cells. Elucidation of
phenotypic variation of CSCs with regards to other tumor
components will provide much needed insight into this hypoth-
esis and may help explain differences in normal and tumor-
related stroma and immune compartments. However, these
ideas remain attractive hypotheses that will require experimental
confirmation.
Thriving under Pressure
Hypoxia has been demonstrated to be a key factor in CSCmain-
tenance in GBMs and neuroblastoma (Li et al., 2009a; Pietras
et al., 2009; Seidel et al., 2010). As hypoxia promotes radioresist-
ance and angiogenesis—both of which are considered CSC
traits—the negative impact of hypoxia on patient survival may
be explained in part by increasedmaintenance of CSCs. Regions
of hypoxia can arise within the tumor due to necrosis or the
failure of tumor vasculature to efficiently exchange oxygen,
even in the perivascular niche. Hypoxia may not only facilitate
GBM CSC maintenance but also promote acquisition of stem-
like characteristics within the tumor (Heddleston et al., 2009).
Molecular responses to hypoxia are commonly governed by
the hypoxia-inducible factors (HIFs), which were linked to
angiogenesis in a rat GBM model and shown to be important
in regulating GBM cell survival (Acker et al., 2005). HIFs are
also critical for GBM and neuroblastoma CSC maintenance
and intimately linked to angiogenesis. Specifically, it has been484 Cell Stem Cell 8, May 6, 2011 ª2011 Elsevier Inc.shown that HIF1a regulates medulloblastoma and GBM CSCs
(Soeda et al., 2009; Pistollato et al., 2010), while HIF2a is specif-
ically expressed in neural CSCs (Li et al., 2009a; Pietras et al.,
2009; Seidel et al., 2010) and promotes stem cell maintenance
and CSC phenotypes (Heddleston et al., 2009). Stabilization of
HIF2a protein under physiologic hypoxia or overexpression of
nondegradable HIF2a increases self-renewal in vitro and tumor
formation in vivo. This effect was observed not only in the initial
CSC subpopulation but also in more differentiated nonstem
tumor cells. Neural stem cells reside within low-oxygen regions
(Mohyeldin et al., 2010) and exhibit a growth dependence on
blood vessels, as shown by Temple and colleagues in a 2004
Science paper (reviewed by Gilbertson and Rich, 2007), sug-
gesting that these key niches are shared by both normal and
neoplastic neural stem cells and that extrinsic regulation from
the microenvironment promotes plasticity within the neoplastic
compartment. Challenges still remain in the definitive anatomical
identification of hypoxic niches due to the rapidly evolving
composition of the tumor and lack of experimental reagents;
however, the molecular mechanisms contributing to the CSC
phenotype via hypoxia are being defined.
Regional and temporal perturbations of the microenvironment
can profoundly modulate resident cellular physiology relative to
steady-state conditions. Attention has been paid to hypoxia
within this context, but other extracellular states may also be
important. Acidic stress, which is not uniform across a tumor,
induces plasticity in nonstem glioma cells, making them more
GBM CSC-like (Hjelmeland et al., 2011). Following exposure to
physiologic tumor pH (6.5), nonstem glioma cells upregulate
stem cell-associated genes and display increased growth and
tumorigenic potential. Similar to the hypoxic situation, these
studies suggest that culturing cells under physiological tumor
conditions rather than artificial conditions that promote unre-
stricted proliferation may maintain cellular heterogeneity better
and perhaps improve the ability to model tumors. Proliferation
in cell culture is limited by glucose availability, leading to routine
use of extremely supraphysiologic glucose concentrations. The
availability of metabolic factors, such as lactate in addition to
glucose, could significantly affect the intrinsic phenotype in
a manner similar to that seen in response to hypoxia and acidic
stress. The elucidation of how the microenvironment regulates
CSC maintenance not only is critical to our understanding of
tumor biology but also provides an opportunity to unravel mech-
anisms of therapeutic resistance. Signals provided by both the
perivascular and hypoxic niches are likely contributing factors,
highlighting the potential of targeting the CSCs through thera-
peutic modalities designed to disrupt the niche.
Keeping an Eye on the Blindside
A hallmark of GBMs and other primary brain tumors is their
propensity to invade into normal brain tissue, which prevents
curative surgical resection. As CSC models may display in vivo
invasion similar to human tumors (Wakimoto et al., 2009), it is
tempting to speculate that the invasive edge may function as
another CSC niche. Detailed examination of this hypothesis
has thus far been limited by a variety of factors, not the least of
which is the challenge of detecting and visualizing the invasive
edge in vivo over time. Other key questions also remain open,
such as whether CSCs migrate faster than nonstem tumor cells.
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imaging may provide the tools necessary to better elucidate
this putative niche. Dissecting this niche has implications
beyond CSC maintenance, as anti-invasive therapies are likely
to be useful in combination with traditional GBM therapeutic
paradigms. There is a risk that CSCs located at the invasive
edge will remain following surgical resection, given that tumor
cells likely exist beyond the margin detectible by current imaging
techniques, and potential cost to normal brain tissue must be
weighed against removal of the tumor margin. Additionally,
better understanding of this niche may clarify the ability for one
niche to repopulate or recreate another niche after therapy.
This analysis of the invasive edge may also represent an oppor-
tunity to understand how immune cells that reside within the
tumor interact with the tumor components (Markovic et al.,
2009), and possibly with the CSCs specifically. Constructing
models to address this relationship at the tumor interface will
address another major limitation of our current knowledge.
The recent work discussed in this review underscores our
evolving understanding of the tumor microenvironment, in that
beyond functioning as a regulator of CSC maintenance, compo-
nents of the niche may also serve as a putative catalyst of the
CSC phenotype. The relationship of tumor cells to the niche is
far from being fully defined. In rapidly evolving neural tumors, it
remains unresolved whether CSCs develop a niche or whether
a niche exists that recruits CSCs. Additional in vivo studies
utilizing high-resolution imagingmodalities and reporter systems
may help resolve this cause-and-effect relationship. Another
relationship yet to be fully defined is the interaction of tumor cells
with the stroma, and it is likely that there exists a bidirectional
relationship. The contribution of CSCs to the invading tumor
margin and possible interactions with the immune system are
additional relationships that are only beginning to be investi-
gated. The plasticity present within tumors has long been noted,
but recent work suggests that evenCSCsmay be plastic and can
be viewed as opportunistic entities readily able to contribute to
their surrounding microenvironment. Gaining insight into
communication mechanisms between CSCs and the microenvi-
ronment will be informative with regards to the contribution of
CSCs to tumor initiation, growth, maintenance, invasion, and
therapeutic resistance. Additionally, these communication
mechanisms are likely to drive the development ofmore effective
therapies for malignant tumors such as GBMs.
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